Background image for the top navigation. About the Cancer Institute Ways to Give page link Cancer Institute Homepage link
Email to a friend    Printer Friendly Page
Text Size: decrease font increase font

Visit the MaineHealth Cancer Resource Center

The Maine Medical Center Cancer Institute - Volume Data

There is a wealth of evidence linking higher volume to better patient outcomes. MMC cares for more patients diagnosed with cancer, including some of the most difficult cases in the state, than any other hospital in Maine. Of the estimated 8,000 people in this state who are diagnosed with cancer each year, more than 2,700 - or one-third - will turn to MMCCI for some aspect of their diagnosis or treatment.

Using Informatics to Improve the Quality of Cancer Care
MMC has what is arguably the most robust medical informatics program in the state. As a Commission on Cancer-accredited institution (MMC is Maine's only teaching hospital to achieve this level of accreditation), the medical center maintains a comprehensive cancer registry. This is a repository of data drawn from medical records on the incidence of cancer, and it includes demographic, pathologic, quality-of-life outcomes and cancer-specific outcomes of patients treated at MMC. The data are continually analyzed to evaluate how specific cancer treatments affect patient outcomes, providing accurate information with which physicians can develop and refine best practices and compare themselves against state and national quality benchmarks. Our data is also used to provide patients with accurate information when they are trying to make a well-informed choice about which treatment to undergo for their cancer.

Volume and Types of Patients with Cancer Diagnosed at Maine Medical Center

Chart 1: Indicates the distribution of cancer case sites for 2013, the most recent year the data is available through the American College of Surgeons' Commission on Cancer (CoC) approved Network Cancer Registry. 

Cancer at MMC in 2013
 Cancer at MMC in 2013
 * malignant (includes lymphoma) + nonmalignant

Chart 2: Among these types of cancers, MMC treats more patients than any other hospital in Maine. For patients, this means your care team at MMC has a level of experience that is unmatched in the state.

Percentage of All Maine Cancers Seen at MMC

Percentage of All Maine Cancers Seen at MMC
* 1-year average based on 2011-2013
** malignant (includes lymphoma) + nonmalignant

Specific information about the types of cancer treated at MMC can also be found by reviewing cancer staging data, which uses a system of numbers and letters to describe how much cancer has spread. This information helps physicians make treatment plans for individual patients. For a more detailed breakdown of the number and percent of cancer cases diagnosed by body part and American Joint Committee on Cancer (AJCC) stage, visit the CoC website at You will be able to search for specific information regarding the cancer program at Maine Medical Center.

Commission on Cancer (CoC) Cancer Program Practice Profile Reports (CP3R)
The Cancer Program Practice Profile Reports (CP3R) have been implemented for the purpose of fostering quality improvement at cancer programs awarded Commission on Cancer Accreditation. As a hospital which has been awarded accreditation as an Academic Comprehensive Cancer Program, Maine Medical Center participates in these studies. The CP3R provides feedback to CoC programs to improve the quality of data as well as clinical management and coordination of patient care in the multidisciplinary setting. In addition, the CP3R is designed specifically to promote quality improvement activities that can assist facilities in the fulfillment of the CoC Accreditation Standards requirements. The estimated performance rates shown below provide an indication of the proportion of breast and colorectal patients treated according to recognized standards of care in diagnosis year 2011.


Breast and Colorectal Measures

   Estimated Performance Rates 2011


 All Teaching

 All CoC-


Radiation therapy is administered within one year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer.


91% 91%
Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1c N0 M0, or Stage II or III ERA and PRA negative breast cancer.  91.3% 90.7% 91.50%
Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c N0 M0, or Stage II or III ERA and/or PRA positive breast cancer. 95.5% 88.2%  88.10% 
Breast conserving surgery rate - patients with clinical or pathological Stage 0, I, II * 65.78%   Data Not Available 60.85% 


Adjuvant chemotherapy is considered or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer.  100.0% 86.5%  88.6% 
At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer. 93.6% 91%  87.70%


Radiation therapy is considered or administered within 6 months (180 days) of diagnosis for patients under the age of 80 with clinical or pathologic AJCC T4N0M0 or Stage III receiving surgical resection for rectal cancer.


92.9% 92.8%

* National Accreditation Program for Breast Centers' benchmark is greater than 50%.
Data Source: CP3R, Commission on Cancer, first released: November 2008, last updated: March 2014.

For a more complete description of the Commission on Cancer Practice Profile Report, please visit the following website: 

22 Bramhall Street | Portland, Maine 04102-3175 | 1-(877)-831-2129